ZYNRELEF combines bupivacaine, an amide-type local anesthetic, with a low dose of meloxicam, a nonsteroidal anti-inflammatory drug, in a proprietary Biochronomer® extended-release polymer that provides controlled diffusion of both ingredients simultaneously for 72 hours at …

ZYNRELEF (bupivacaine and meloxicam) extended-release solution is available in four dosage strengths as single-dose glass vials: • 400 mg bupivacaine and 12 mg meloxicam Concomitant use with ZYNRELEF may diminish the antihypertensive effect • 300 mg bupivacaine and 9 mg meloxicam • 200 mg bupivacaine and 6 mg meloxicam

ZYNRELEF is indicated in adults for instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.

ZYNRELEF patients experienced superior pain relief through 72 hours—when pain is most severe—compared to patients receiving the current standard of care, bupivacaine HCl solution, making ZYNRELEF the first and only product to demonstrate superiority over bupivacaine HCl solution in Phase 3 studies.

ZYNRELEF is indicated in adults for instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.

ZYNRELEF is indicated in adults for instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.

Get the answers to your ZYNRELEF questions here. Don’t see your question? Contact a Heron Therapeutics representative to find out more

ZYNRELEF is indicated in adults for instillation to produce postsurgical analgesia for up to 72 hours after soft tissue and orthopedic procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.

Coverage for ZYNRELEF varies by health insurance plan and site of care. Reimbursement of ZYNRELEF in a surgical procedure occurring during a hospital inpatient admission would be included in the diagnosis-related group (DRG) payment. The table below summarizes the coverage and payment type for HOPDs.

ZYNRELEF is approved for use in adults to reduce pain for up to 3 days after removal of bunions, groin hernia repair, and total knee replacement. ZYNRELEF is applied into the wound at the time of surgery.1 ZYNRELEF is a non-opioid that reduces or eliminates the need for opioids in many